- Home
- LINC vs ANAB Comparison
LINC vs ANAB Comparison
Compare LINC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LINC
- ANAB
- Stock Information
- Founded
- LINC 1946
- ANAB 2005
- Country
- LINC United States
- ANAB United States
- Employees
- LINC N/A
- ANAB N/A
- Industry
- LINC Other Consumer Services
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- LINC Real Estate
- ANAB Health Care
- Exchange
- LINC Nasdaq
- ANAB Nasdaq
- Market Cap
- LINC 710.1M
- ANAB 659.6M
- IPO Year
- LINC 2005
- ANAB 2017
- Fundamental
- Price
- LINC $21.79
- ANAB $30.93
- Analyst Decision
- LINC Strong Buy
- ANAB Buy
- Analyst Count
- LINC 4
- ANAB 10
- Target Price
- LINC $24.50
- ANAB $50.63
- AVG Volume (30 Days)
- LINC 353.6K
- ANAB 737.6K
- Earning Date
- LINC 11-10-2025
- ANAB 11-04-2025
- Dividend Yield
- LINC N/A
- ANAB N/A
- EPS Growth
- LINC 79.82
- ANAB N/A
- EPS
- LINC 0.46
- ANAB N/A
- Revenue
- LINC $467,763,000.00
- ANAB $123,164,000.00
- Revenue This Year
- LINC $14.51
- ANAB $11.40
- Revenue Next Year
- LINC $8.40
- ANAB $8.17
- P/E Ratio
- LINC $47.62
- ANAB N/A
- Revenue Growth
- LINC 14.53
- ANAB 304.17
- 52 Week Low
- LINC $11.63
- ANAB $12.21
- 52 Week High
- LINC $25.76
- ANAB $36.54
- Technical
- Relative Strength Index (RSI)
- LINC 52.14
- ANAB 71.43
- Support Level
- LINC $21.43
- ANAB $29.49
- Resistance Level
- LINC $23.16
- ANAB $32.24
- Average True Range (ATR)
- LINC 0.71
- ANAB 2.08
- MACD
- LINC -0.05
- ANAB 0.81
- Stochastic Oscillator
- LINC 38.58
- ANAB 82.04
About LINC Lincoln Educational Services Corporation
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include; Campus Operations, and Transitional. The majority of the revenue is generated from the Campus Operations segment which includes all campuses that are continuing in operation and contribute to the Company's core operations and performance.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).